他克莫司血浆与全血浓度联合药代动力学模型:肾与肺移植受者
基于1060例移植受者的1973份血浆和1961份全血样本,建立群体药代动力学模型,以可饱和结合方程连接血浆与全血他克莫司浓度。模拟显示全血目标范围内患者对应的血浆浓度:肾移植0.06-0.26 ng/mL,肺移植0.10-0.93 ng/mL。
要点
- 全血他克莫司目标范围可转换为血浆浓度范围用于TDM。
- 肾移植全血4-6 ng/mL对应血浆0.06-0.26 ng/mL。
- 肺移植全血7-10 ng/mL对应血浆0.10-0.93 ng/mL。
核心结论
- 当前全血他克莫司目标范围可转换为血浆浓度范围:肾移植0.06-0.26 ng/mL,肺移植0.10-0.93 ng/mL。
研究设计与样本
- 基于TransplantLines生物样本库与队列研究,纳入1060例肾或肺移植受者,测定血浆(n=1973)和全血(n=1961)他克莫司浓度。
- 采用非线性混合效应模型建立群体药代动力学模型,并进行模拟推断血浆浓度范围。
主要发现
- 一室模型(固定一级吸收、估计一级消除)可描述血浆浓度,血浆与全血通过可饱和结合方程连接。
- 可饱和结合参数:最大结合35.7 ng/mL(95%CI 31.0-40.4 ng/mL),解离常数0.24 ng/mL(95%CI 0.19-0.29 ng/mL)。
关键数值与推荐
- 肾移植全血目标浓度4-6 ng/mL,对应血浆浓度95%预测区间0.06-0.26 ng/mL。
- 肺移植全血目标浓度7-10 ng/mL,对应血浆浓度95%预测区间0.10-0.93 ng/mL。
临床怎么用
- 临床可参考上述血浆浓度范围,将全血TDM目标转换为血浆TDM目标。
- 血浆浓度可能更好反映游离暴露,但需结合临床评估使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Historically, dosing of tacrolimus is guided by therapeutic drug monitoring (TDM) of the whole blood concentration, which is strongly influenced by haematocrit. The therapeutic and adverse effects are however expected to be driven by the unbound exposure, which could be better represented by measuring plasma concentrations. OBJECTIVE: We aimed to establish plasma concentration ranges reflecting whole blood concentrations within currently used target ranges. METHODS: Plasma and whole blood tacrolimus concentrations were determined in samples of transplant recipients included in the TransplantLines Biobank and Cohort Study. Targeted whole blood trough concentrations are 4-6 ng/mL and 7-10 ng/mL for kidney and lung transplant recipients, respectively. A population pharmacokinetic model was developed using non-linear mixed-effects modelling. Simulations were performed to infer plasma concentration ranges corresponding to whole blood target ranges. RESULTS: Plasma (n = 1973) and whole blood (n = 1961) tacrolimus concentrations were determined in 1060 transplant recipients. A one-compartment model with fixed first-order absorption and estimated first-order elimination characterised observed plasma concentrations. Plasma was linked to whole blood using a saturable binding equation (maximum binding 35.7 ng/mL, 95% confidence interval (CI) 31.0-40.4 ng/mL; dissociation constant 0.24 ng/mL, 95% CI 0.19-0.29 ng/mL). Model simulations indicate that patients within the whole blood target range are expected to have plasma concentrations (95% prediction interval) of 0.06-0.26 ng/mL and 0.10-0.93 ng/mL for kidney and lung transplant recipients, respectively. CONCLUSION: Whole blood tacrolimus target ranges, currently used to guide TDM, were translated to plasma concentration ranges of 0.06-0.26 ng/mL and 0.10-0.93 ng/mL for kidney and lung transplant recipients, respectively.
引用
- Koomen JV, Knobbe TJ, Zijp TR, et al. A Joint Pharmacokinetic Model for the Simultaneous Description of Plasma and Whole Blood Tacrolimus Concentrations in Kidney and Lung Transplant Recipients. Clin Pharmacokinet. 2023. PMID: 37306899. doi:10.1007/s40262-023-01259-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。